Wenceslau Cristiane Valverde, Dias Câmara Diana Aparecida, de Oliveira Damiana Pedro, Pinheiro Rodrigo Araldi, Kerkis Irina
Knowledge regarding the spatiotemporal distribution of cells that express pluripotent and Progenitor-Neural Stem Cell Markers (PNSC) is vital for understanding their role in various stages of embryonic brain development. However, there are few data that connect these markers’ expression with the developmental stage in the mouse brain. We investigated the expression of pluripotent cell markers (Oct4, Nanog, and Sox2) and PNSC markers (Sox 1; nestin, vimentin, GFAP) in mice brains on Embryonic (E) days E9.5, E12.5, E15.5 and E18.5 and in the mature adult brain. We observed the expression of all studied markers in rostral and caudal neuropores at E9.5. The cells at E12.5 in primary brain vesicles showed only expression of four markers: Oct4, Sox2, vimentin and nestin. In addition, hindbrain cells express Sox1 and midbrain – Fragilis. The Ventricular Zone (VZ) at E15.5 and E18.5 shared the expression of Oct 4, Sox 2, Sox1, nestin, and GFAP, besides at E18.5 VZ expressed Fragilis. The olfactory bulb (OB) at E18.5 showed the expression of Sox2, Nanog, Fragilis, Nestin, and GFAP. In the adult brain, the sub-VZ (SVZ) showed expression of all studied markers, but not for Sox2 and Nanog; OB is positive for Nestin only, while cerebellum for Sox1 and Sox2. Neuropores in embryonic and the Subventricular Zone (SVZ) in adult brains express the most considerable number of studied markers, suggesting less cell specification. SVZ is a stem cell niche in the adult brain. Oct4, Sox2 and Nestin seem indispensable during brain development and in the adult brain in mice.
{"title":"Differential expression of markers of pluripotency and neural/progenitor cells throughout embryonic brain development in mice","authors":"Wenceslau Cristiane Valverde, Dias Câmara Diana Aparecida, de Oliveira Damiana Pedro, Pinheiro Rodrigo Araldi, Kerkis Irina","doi":"10.17352/sscrt.000020","DOIUrl":"https://doi.org/10.17352/sscrt.000020","url":null,"abstract":"Knowledge regarding the spatiotemporal distribution of cells that express pluripotent and Progenitor-Neural Stem Cell Markers (PNSC) is vital for understanding their role in various stages of embryonic brain development. However, there are few data that connect these markers’ expression with the developmental stage in the mouse brain. We investigated the expression of pluripotent cell markers (Oct4, Nanog, and Sox2) and PNSC markers (Sox 1; nestin, vimentin, GFAP) in mice brains on Embryonic (E) days E9.5, E12.5, E15.5 and E18.5 and in the mature adult brain. We observed the expression of all studied markers in rostral and caudal neuropores at E9.5. The cells at E12.5 in primary brain vesicles showed only expression of four markers: Oct4, Sox2, vimentin and nestin. In addition, hindbrain cells express Sox1 and midbrain – Fragilis. The Ventricular Zone (VZ) at E15.5 and E18.5 shared the expression of Oct 4, Sox 2, Sox1, nestin, and GFAP, besides at E18.5 VZ expressed Fragilis. The olfactory bulb (OB) at E18.5 showed the expression of Sox2, Nanog, Fragilis, Nestin, and GFAP. In the adult brain, the sub-VZ (SVZ) showed expression of all studied markers, but not for Sox2 and Nanog; OB is positive for Nestin only, while cerebellum for Sox1 and Sox2. Neuropores in embryonic and the Subventricular Zone (SVZ) in adult brains express the most considerable number of studied markers, suggesting less cell specification. SVZ is a stem cell niche in the adult brain. Oct4, Sox2 and Nestin seem indispensable during brain development and in the adult brain in mice.","PeriodicalId":227339,"journal":{"name":"Studies on Stem Cells Research and Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121493233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In recent past, several research papers mentioned that stem cells can cure ailments of even serious nature whether acute or chronic in humans and also in other animals. Basic and clinical research accomplished during the last few years on embryonic, fetal, amniotic, umbilical cord blood, and adult stem cells has constituted a revolution in regenerative medicine and cancer therapies by providing the possibility of generating multiple therapeutically useful cell types. These new cells could be used for treating numerous genetic and degenerative disorders. Among them, age-related functional defects, hematopoietic and immune system disorders, heart failures, chronic liver injuries, diabetes, Parkinson’s and Alzheimer’s diseases, arthritis, and muscular, skin, lung, eye, and digestive disorders as well as aggressive and recurrent cancers could be successfully treated by stem cell-based therapies [1-5].
{"title":"Stem Cell – De Novo Treatment Disorders","authors":"AD Diwan, SN Harke","doi":"10.17352/sscrt.000018","DOIUrl":"https://doi.org/10.17352/sscrt.000018","url":null,"abstract":"In recent past, several research papers mentioned that stem cells can cure ailments of even serious nature whether acute or chronic in humans and also in other animals. Basic and clinical research accomplished during the last few years on embryonic, fetal, amniotic, umbilical cord blood, and adult stem cells has constituted a revolution in regenerative medicine and cancer therapies by providing the possibility of generating multiple therapeutically useful cell types. These new cells could be used for treating numerous genetic and degenerative disorders. Among them, age-related functional defects, hematopoietic and immune system disorders, heart failures, chronic liver injuries, diabetes, Parkinson’s and Alzheimer’s diseases, arthritis, and muscular, skin, lung, eye, and digestive disorders as well as aggressive and recurrent cancers could be successfully treated by stem cell-based therapies [1-5].","PeriodicalId":227339,"journal":{"name":"Studies on Stem Cells Research and Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127028562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Our objective in this study is to compare the outcomes of patients with multiple myeloma (MM) over 65 years of age who had autologous hematopoietic stem cell transplantation (AHSCT) with the outcomes of patients under 65 years of age.
{"title":"Evaluation of success and toxicity of autologous stem cell transplantation in patients with multiple myeloma in the geriatric age group","authors":"M. Ucar, S. Dagdas, F. Ceran, M. Falay, G. Özet","doi":"10.17352/sscrt.000012","DOIUrl":"https://doi.org/10.17352/sscrt.000012","url":null,"abstract":"Background: Our objective in this study is to compare the outcomes of patients with multiple myeloma \u0000(MM) over 65 years of age who had autologous hematopoietic stem cell transplantation (AHSCT) with the \u0000outcomes of patients under 65 years of age.","PeriodicalId":227339,"journal":{"name":"Studies on Stem Cells Research and Therapy","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127975990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：